CALIFORNIA – Oct 23, 2023 – In the dynamic landscape of medical research, Angiopoietin-Related Protein 2 (ANGPTL2) emerges as a versatile biomarker with immense potential particularly in immunity. This comprehensive press release examines the three pivotal aspects of ANGPTL2 research: the discovery of ANGPTL2, the development of advanced antibody assays and lastly, the groundbreaking insights into its role in innate immunity.
The Discovery of ANGPTL2
Angiopoietin-like 2 (ANGPTL2) is a member of the angiopoietin-like family, a group of glycoproteins with structural similarities to angiopoietins. Its characteristic structure consists of an N-terminal coiled-coil domain, a short linker peptide, and a C-terminal fibrinogen-like domain. ANGPTL2 was initially cloned, expressed, and characterized in 1999, emerging as a glycosylated protein composed of 493 amino acids, with a molecular weight of 57 kDa (64 kDa with glycosylations).
Moreover, ANGPTL2 boasts a sequence identity of 95% with its mouse counterpart, 59% with human ANGPTL1, 35% with mouse Angptl3 and human ANGPTL4, and 34% with human ANGPTL1 and ANGPTL2. When expressed in mammalian cells, recombinant ANGPTL2 exhibits the remarkable traits of secretion and glycosylation. Western blot analysis pinpoints the molecular mass of recombinant ANGPTL2 at approximately 64 kD.
Research suggests that ANGPTL2 can be cleaved into domain fragments by the tolloid-like 1 protease, potentially leading to inactivation, particularly observed in cultured cancer cells. This versatile protein finds expression in various tissues and is secreted into the systemic circulation.
Over the years, ANGPTL2 has evolved from a significant biomarker to a central focus of scientific inquiry. Its potential applications in health and disease have become increasingly apparent, driving the development of advanced antibody assays and fostering groundbreaking insights into its roles in innate immunity.
ANGPTL2 in Advanced Antibody Assays
Advanced antibody assays including Western Blot (WB), ELISA, Flow Cytometry, and Immunocytochemistry (IHC), now play a pivotal role in unraveling the intricacies of ANGPTL2. These assays feature meticulously designed antibodies, whether polyclonal or monoclonal, tailored to exclusively target ANGPTL2. This unwavering specificity ensures the accuracy of results across diverse biological contexts.
Tailoring Experiments for Every Study
Researchers exploring ANGPTL2 now have a versatile range of antibodies at their disposal. This adaptability enables the customization of experiments to meet the unique demands of each study. Whether ANGPTL2 is under investigation in human, mouse, rat, or other animal samples, there exists an antibody perfectly suited to the research objectives.
Mouse and Rabbit Antibodies at the Core
Boster’s commitment to advancing ANGPTL2 research is exemplified by their primary use of antibodies sourced from mouse and rabbit hosts. These meticulously crafted and rigorously validated antibodies serve as the cornerstone of advanced assays, propelling groundbreaking discoveries in ANGPTL2 science.
ANGPTL2’s Role in Innate Immunity
Macrophages play an indispensable role in the innate immune system, serving as frontline defenders against pathogens. Their ability to promote inflammation and phagocytosis is pivotal for an immediate response to infectious threats. ANGPTL2 is at the heart of this process.
Inflammatory Signaling and Proinflammatory Activity
Recent research reveals that ANGPTL2 is predominantly expressed in proinflammatory mouse bone marrow-derived macrophages (GM-BMMs) following GM-CSF treatment. This groundbreaking discovery indicates a potential role for ANGPTL2 in enhancing proinflammatory activity within macrophages.
ANGPTL2’s impact on proinflammatory markers in GM-BMMs from Angptl2-deficient mice compared to wild-type (WT) mice suggests a potential attenuation of proinflammatory activity. Furthermore, ANGPTL2’s inflammatory signaling is transduced through integrin α5β1, rather than through paired immunoglobulin-like receptor B. Additionally, Angptl2-deficient mice exhibit increased susceptibility to Salmonella enterica serovar Typhimurium infection, underlining its role in fighting infections by promoting nitric oxide (NO) production.
Implications for ANGPTL2 Research
The groundbreaking insights into ANGPTL2’s involvement in innate immunity, sheds light on its potential significance in bolstering proinflammatory responses required to combat infections. Researchers seeking to embark on ANGPTL2 research or expand their existing studies can explore Boster’s extensive range of Picoband® ANGPTL2 antibodies. These antibodies have been meticulously engineered and rigorously screened to exhibit high affinity for the target protein while minimizing cross-reactivity across various tissues and species. This precision enhancement facilitates more accurate research outcomes and unlocks fresh perspectives for understanding ANGPTL2 in diverse contexts.
For more information, visit our official website athttps://www.bosterbio.com/bosterbio-gene-info-cards/ANGPTL2 where you can explore a range of ANGPTL2 antibodies that suits your experiment.
About Boster Bio
Boster (bosterbio.com) has organically grown into one of the top 10 antibody companies globally with 30 years of expertise offering state-of-the-art ELISA kits, antibodies, custom reagents and analytical services in immunology, sequencing, cancer research and more. Boster’s proprietary technologies like the PCD platform and products have been well-cited in over 50,000 publications.
References:
Media ContactCompany Name: BOSTERContact Person: CJ XiaEmail: Send EmailPhone: (888) 466-3604Country: United StatesWebsite: www.bosterbio.com
